Acrivon Q2 FY26 net loss narrows 14.48% to $18 million
Reuters2026/08/12 20:08- Acrivon Therapeutics posted a Q2 net loss of USD 18 million, narrowing from USD 21 million a year earlier.
- R&D expense fell to USD 13.8 million from USD 16.2 million, on non-recurring ACR-368 milestone costs booked in 2025.
- G&A expense declined to USD 4.8 million from USD 6.5 million, driven by lower employee-related costs including stock-based compensation.
- Cash, cash equivalents, marketable securities totaled USD 90 million at June 30, expected to fund operations into Q4 2027.
- ACR-368 Phase 2b interim analysis remains on track for H2 2026; ACR-2316 moved into randomized dose expansion with 120 mg and 160 mg.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Japanese Yen consolidates near August highs vs USD as hawkish BoJ, Fed bets clash
The 10-year U.S. Treasury yield climbs to 4.8%, erasing the dividend advantage of utility stocks; the sector’s rebound depends on interest rate stabilization rather than technical signals.
As U.S. Treasury yields continue to climb, the American utilities sector is experiencing a significant pullback—a rise in yields not only erodes the relative appeal of the sector’s dividends but also raises financing costs for the most capital-intensive industries within this market.
Euro holds gains above 1.1600 despite robust US jobs data, traders eye ECB rate decision
Crypto prices
More
